IAP antagonists potentiate TNFα-triggered apoptosis but selectively eliminate senescent tumor cells independently of TNFα
Preprint
Abstract
Therapy-induced senescence (TIS) is a state of cell division arrest induced by chemotherapy that blocks tumor growth. TIS tumor cells affect the tumor microenvironment through their senescence-associated secretory phenotype and independently acquire stemness, which makes them more aggressive and causes relapse once they regrow. To eradicate tumors by chemotherapy, long-lived TIS tumor cells must be efficiently eliminated. Here, we show that AZD5582 and AT406, which are potent antagonists of inhibitor of apoptosis proteins (IAP antagonists) that suppress the activities of cellular inhibitor of apoptosis protein 1 (cIAP1), cellular inhibitor of apoptosis protein 2 (cIAP2), and X-linked inhibitor of apoptosis protein (XIAP), selectively induced apoptosis mediated by caspase 8 and effector caspases in TIS tumor cells, which produced and secreted tumor necrosis factor α (TNFα). However, these IAP antagonists were still selectively cytotoxic to TIS tumor cells even when TNFα was absent (TNFα-knockout cells) or neutralized (by a neutralizing antibody), indicating they have TNFα-independent senolytic activity. Consistently, these IAP antagonists also sensitized tumor cells that had been induced to become senescent by nutlin-3a, which activates p53 but does not trigger TNFα production. Furthermore, TNFα sensitized tumor cells treated with these IAP antagonists irrespective of their senescence status. Collectively, these data indicate that IAP antagonists that inhibit cIAPs and XIAP not only potentiate TNFα-triggered apoptosis but also have TNFα-independent senolytic activity. We propose that IAP antagonists are good concomitant drugs of chemotherapy that induces TIS, not only as senolytic drugs but also as sensitizers of adjacent non-senescent tumor cells mediated by paracrine TNFα.Keywords
This publication has 57 references indexed in Scilit:
- Death-seq identifies regulators of cell death and senolytic therapiesCell Metabolism, 2023
- Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neckCancer Treatment Reviews, 2022
- Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interactionMolecular Oncology, 2020
- Directed elimination of senescent cells attenuates development of osteoarthritis by inhibition of c-IAP and XIAPBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- Senescence Elicits Stemness: A Surprising Mechanism for Cancer RelapseCell Metabolism, 2018
- IAP Antagonists Target cIAP1 to Induce TNFα-Dependent ApoptosisCell, 2007
- IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent ApoptosisCell, 2007
- Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced ApoptosisCancer Cell, 2007
- Senescent Cells, Tumor Suppression, and Organismal Aging: Good Citizens, Bad NeighborsCell, 2005
- Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP InhibitionCell, 2000